Baglivo et al. also indicated that RET rearrangements could predict a lack of response to ICI monotherapy in NSCLC, citing two cases that experienced rapid disease progression when treated with ICIs, even though they had high levels of programmed death-ligand 1 (PD-L1) [17]. This evidence concerns the gene RET and non-small cell lung carcinoma.